Episode # 219 • 11 Mar 2025
GU ASCO Highlights: Key Takeaways for Clinicians
Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year’s meeting.
This podcast is supported by
Timestamps
00:00 - Introduction
09:20 - TALAPRO-2 Trial Insights
19:29 - Bladder Cancer: Immuno-Oncology Combinations and HER2
27:42 - NIAGARA and iNDUCT Trials
33:32 - Future Directions in Upper Tract Treatment
37:38 - Biomarkers in Kidney Cancer: KIM-1
46:43 - COSMIC-313: Triplet Therapy in Renal Cell Carcinoma
52:39 - Concluding Thoughts and Future Directions
Resources
You may also like
More about this episode
First, the doctors cover a wide range of topics including PARP inhibitors for prostate cancer, HER2-targeting antibody drug conjugates in bladder cancer, adjuvant chemotherapy for upper tract urothelial carcinoma, and biomarkers such as KIM-1 in kidney cancer. Highlighting the importance of multidisciplinary collaboration, the experts also critique the COSMIC-313 trial and discuss the nuances of applying new therapeutic combinations in real-world clinical practice.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.